Emmaus Life Sciences, Inc.
EMMA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $16,653 | $29,597 | $18,390 | $20,610 |
| % Growth | -43.7% | 60.9% | -10.8% | – |
| Cost of Goods Sold | $1,201 | $1,342 | $2,588 | $3,312 |
| Gross Profit | $15,452 | $28,255 | $15,802 | $17,298 |
| % Margin | 92.8% | 95.5% | 85.9% | 83.9% |
| R&D Expenses | $657 | $1,189 | $1,725 | $4,110 |
| G&A Expenses | $10,687 | $14,891 | $13,170 | $13,438 |
| SG&A Expenses | $16,689 | $23,526 | $20,663 | $19,316 |
| Sales & Mktg Exp. | $6,002 | $8,635 | $7,493 | $5,878 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $17,346 | $24,715 | $22,388 | $23,426 |
| Operating Income | -$1,894 | $3,540 | -$6,586 | -$6,128 |
| % Margin | -11.4% | 12% | -35.8% | -29.7% |
| Other Income/Exp. Net | -$4,530 | -$7,332 | -$3,979 | -$9,793 |
| Pre-Tax Income | -$6,424 | -$3,792 | -$10,565 | -$15,921 |
| Tax Expense | $29 | -$59 | $60 | $25 |
| Net Income | -$6,453 | -$3,733 | -$10,625 | -$15,946 |
| % Margin | -38.7% | -12.6% | -57.8% | -77.4% |
| EPS | -0.1 | -0.07 | -0.21 | -0.32 |
| % Growth | -42.2% | 66.5% | 34.4% | – |
| EPS Diluted | -0.1 | -0.07 | -0.21 | -0.32 |
| Weighted Avg Shares Out | 63,235 | 53,105 | 49,440 | 49,253 |
| Weighted Avg Shares Out Dil | 63,235 | 53,105 | 49,440 | 49,253 |
| Supplemental Information | – | – | – | – |
| Interest Income | $274 | $681 | $680 | $761 |
| Interest Expense | $5,492 | $7,383 | $5,013 | $3,101 |
| Depreciation & Amortization | $22 | $32 | $53 | $59 |
| EBITDA | -$910 | $3,623 | -$5,499 | -$12,761 |
| % Margin | -5.5% | 12.2% | -29.9% | -61.9% |